How do collaborators who donate compounds or research tools benefit from this Initiative?
Organizations co-developing compounds with the Initiative or contributing research tools will receive added value in new information on their products as well as assist the Initiative’s research process. This information may have potential use in developing the compounds for other indications. Those who donate compounds that may eventually prove useful against TB for the developing world will retain their intellectual property rights and may market in developed nations. Everybody wins. Researchers working on promising compounds may apply to use NIH-sponsored core resources established to serve the entire TB research community. These include generation and testing of mutant strains, genome sequences of multiple strains of TB [including recent extensively drug-resistant TB (XDR-TB) strains from South Africa], microarrays, structural genomics, rational drug design via x-ray crystallography, bioinformatics, in vivo and in vitro screening for efficacy, in vitro and in vivo PK/PD models, dru
